IMVT-1402

Phase 3Small molecule

IImmunovant Sciences GmbH

IMVT-1402 is one of 63 small molecule programs targeting Graves disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Graves DiseaseRecruiting

Subacute Cutaneous Lupus ErythematosusActive, not recruiting

Generalized Myasthenia GravisRecruiting

Rheumatoid ArthritisActive, not recruiting

Graves DiseasePhase 2

Recruiting

Subacute Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Generalized Myasthenia GravisPhase 3

Recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

IMVT-1402

IImmunovant Sciences GmbH

Phase 3

1 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Cataflam

Plaquenil

Voltaren

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Subacute Cutaneous Lupus Erythematosus

NCT06980805

Phase 2Recruiting

Graves Disease

NCT07018323

Q3 2027

Phase 2Active, not recruiting

Rheumatoid Arthritis

NCT06754462

Q2 2028

Phase 2Recruiting

Graves Disease

NCT06727604

Q4 2028

Phase 3Recruiting

Generalized Myasthenia Gravis

NCT07039916

Clinical

Trials by Indication[1]

Graves disease3 trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06727604·240 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07018323·210 enrolled

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Enrolling by invitation·IImmunovant Sciences GmbH·Phase 2·NCT07286006·372 enrolled

Rheumatoid Arthritis1 trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06754462·120 enrolled

Primary Sjögren's Syndrome1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06979531·180 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07032662·162 enrolled

Subacute Cutaneous Lupus Erythematosus1 trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06980805·56 enrolled

1 more indication

Generalized Myasthenia Gravis1 trial

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

Recruiting·IImmunovant Sciences GmbH·Phase 3·NCT07039916·231 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for IMVT-1402. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMVT-1402 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMVT-1402. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunovant Sciences GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImmunovant Sciences GmbH

IMVT-1402

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Graves disease3 trials

Rheumatoid Arthritis1 trial

Primary Sjögren's Syndrome1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Subacute Cutaneous Lupus Erythematosus1 trial

Generalized Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News